This implies that tumor-promoting effects of Nrf2 are confined competitively by Nrf1, acting as a dominant tumor repressor; this is further corroborated by the evidence showing that no increments in the malignance of liver cancer results from a constitutively active mutant caNrf2ΔN in the presence of Nrf1 [23]. The gene discussed is NFE2L2; the disease is liver cancer.